ARROTEX Pharmaceuticals has entered into a licensing agreement with Taiwan-based Formosa Pharmaceuticals for exclusive rights to the commercialisation of an innovative ophthalmic suspension in Australia and NZ.
The active ingredient is a super-potent corticosteroid derived from Formosa Pharmaceuticals' proprietary APNT nanoparticle formulation platform, which uses salts or sugars for milling pharmaceuticals, rather than metal or plastic beads.
"This agreement with Formosa Pharmaceuticals strengthens our expanding portfolio in specialist care and reinforces our ambition to deliver meaningful innovation to patients," said Arrotex CEO Matt Zeller.
"As Australia's partner in health, we will leverage our national ophthalmology footprint and unique infrastructure, ensuring medicines reach the people who need them most.
"We look forward to working with Formosa," he concluded.
The above article was sent to subscribers in Pharmacy Daily's issue from 24 Feb 26
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Feb 26
